Experience
- Unmatched clinical experience in over 80 million MR procedures worldwide
- Most widely studied contrast agent with more than 14,000 citations in scientific literature
- No interference with serum calcium measurements
Leadership
- MR market leader with a broad range of adult and pediatric clinical indications
- The only MR imaging contrast agent available in 50 mL and 100 mL Pharmacy Bulk Packages with 24-hour time of use.
- Commitment to educational leadership - highly ranked for product service and support
Vision
- Versatile MR imaging contrast agent, evolving for the future
- Corporate dedication to helping physicians better manage patient care
- Commitment to innovative products, educational programs and partnerships for the radiology community
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for Nephrogenic Systemic Fibrosis (NSF) in patients with:
- Acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73 m2), or
- Acute renal insufficiency of any severity due to the hepatorenal syndrome or in the perioperative liver transplantation period
In these patients, avoid use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with non-contrast enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests. When administering a gadolinium-based contrast agent, do not exceed the recommended dose and allow a sufficient period of time for elimination of the agent from the body prior to any readministration.
MAGNEVIST® (gadopentetate dimeglumine) injection: As with other contrast media, the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered. As with other paramagnetic contrast agents, caution should be exercised in patients with renal insufficiency due to the possibility of further deterioration in renal function. As with other injectable products, cases of phlebitis and thrombophlebitis have been reported; assessment of the dosed limb for the development of injection site reactions is recommended.
|
